Appropriate targets for monoclonal antibodies in the induction of transplantation tolerance.
There are many routes to exploiting tolerance processes to ensure long-term graft survival. Complete tolerance although attractive as a goal, may not be the most practical in the clinic. Instead simple and low-impact procedures that harness tolerance processes used in conjunction with low doses of immunosuppressive drugs may prove the most reliable and user-friendly of approaches.
Waldmann
H
H
Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK. herman.waldmann@pathology.ox.ac.uk
Hale
G
G
Cobbold
S
S
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D015703:Antigens, CD / Q000276:immunology; D000951:Antigens, Neoplasm; D016026:Bone Marrow Transplantation / Q000276:immunology; D015704:CD4 Antigens / Q000276:immunology; D000074301:CD52 Antigen; D016827:CD8 Antigens / Q000276:immunology; D006023:Glycoproteins / Q000276:immunology; D006084:Graft Rejection / Q000276:immunology; D006086:Graft vs Host Disease / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D008212:Lymphocyte Depletion; D018448:Models, Immunological; D023001:Transplantation Tolerance / Q000276:immunology*
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D015704:CD4 Antigens; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D016827:CD8 Antigens; D006023:Glycoproteins